Early this morning, OncoGenex announced the result of final analysis of data from the Phase III AFFINITY trial of custirsen + cabazitaxel + prednisone in men with metastatic, castration-resistant prostate cancer (mCRPC) who had progressed after docetaxel chemotherapy.
According to the company’s media release, and in line with results from two prior Phase III trials of custirsen in late-stage forms of prostate cancer, the trial showed no benefit favoring the use of custirsen + cabazitaxel + prednisone compared to cabazitaxel + prednisone.
This trial was always a “long-shot” for OncoGenex after the negative results from the two earlier Phase III studies in men with less advanced forms of metastatic prostate cancer. The company will not be pursuing any other studies to try to demonstrate effectiveness of custirsen in prostate cancer.
Filed under: Drugs in development | Tagged: castration-resistant, custirsen, mCRPC, metastatic, OncoGenex |
THE "NEW" PROSTATE CANCER INFOLINK 
Leave a Reply